Ryan E. Wiegand

Effectiveness of RSV Prevention Strategies in US Infants: 2024–2025

OBJECTIVE: In 2023, 2 products, a long-acting monoclonal antibody (nirsevimab) and maternal respiratory syncytial virus (RSV) vaccination, were recommended in the United States to prevent severe RSV disease among infants in their first RSV season. Low uptake during the 2023 to 20...